

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

10308B

In Re Application Of: Leonard Harrison, et al.

JUL 18 2006

Application No. Filing Date

10/040,815

January 7, 2002

Examiner

Gerald R. Ewoldt

Customer No.

23389

Group Art Unit

1644

Confirmation No.

4822

Title: IMMUNOREACTIVE AND IMMUNOTHERAPEUTIC MOLECULES

Address to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);


OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
10308B

In Re Application of: Leonard Harrison, et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/040,815	January 7, 2002	Gerald R. Ewoldt	23389	1644	4822

Title: IMMUNOREACTIVE AND IMMUNOTHERAPEUTIC MOLECULES

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

July 12, 2006
(Date)

Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: July 12, 2006

Xiaochun Zhu
Registration No. 56,311
Scully, Scott, Murphy & Presser, P. C.
400 Garden City Plaza-STE 300
Garden City, New York 11530
(516) 742-4343

cc: XZ:ab



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Leonard Harrison, et al

Examiner: Gerald R. Ewoldt

Serial No.: 10/040,815

Art Unit: 1644

Filed: January 7, 2002

Docket: 10308B

For: IMMUNOREACTIVE AND
IMMUNOTHERAPEUTIC MOLECULES

Dated: July 12, 2006

Confirmation No.: 4822

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is respectfully requested that the following disclosures, which are also listed on the attached form PTO-1449 be made of record in the above-identified case.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 12, 2006.

Dated: July 12, 2006


Xiaochun Zhu

1. European Patent Publication No. 0 171 886A, published February 19, 1986;
and
2. Rudy, G. et al., "Similar Peptides from Two β Cell Autoantigens, Proinsulin and Glutamic Acid Decarboxylase, Stimulate T Cells of Individuals at Risk for Insulin-Dependent Diabetes", *Molecular Medicine*, 1(6): 625-633 (1995), XP000607204.

The references were cited in a Supplementary Partial European Search Report dated December 13, 2000. Applicants are submitting copies of the above-cited references, together with a copy of the Supplementary Partial Search Report. The relevance of the above-identified references has been described in the Supplemental Partial European Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b)(4), no statement or fee is required.

Respectfully submitted,




Xiaochun Zhu
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza-STE 300
Garden City, New York 11530
(516) 742-4343
XZ:ab

**LIST OF PRIOR ART
CITED BY APPLICANT**

(Use several sheets if necessary)

**Atty. Docket No.**
10308B**Serial No.**
10/040,815**Applicants**
Leonard Harrison, et al.**Filing Date**
January 7, 2002**Group**
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
	AC						
	AD						
	AE						

		Foreign Document Number	Date	Country	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		EP 0171886A	2/19/86	EPO				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		Rudy, G. et al., "Similar Peptides from Two β Cell Autoantigens, Proinsulin and Glutamic Acid Decarboxylase, Stimulate T Cells of Individuals at Risk for Insulin-Dependent Diabetes", <i>Molecular Medicine</i> , 1(6): 625-633 (1995), XP000607204

EXAMINER**DATE CONSIDERED**

* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.